{"entity":{"id":"hmpl-306","kind":"drug","name":"HMPL-306","aka":["HMPL-306 Regimen"],"tldr":"HMPL-306 is an experimental small-molecule drug from Hutchmed in phase 3 trials for acute myeloid leukaemia, aimed at IDH1 / IDH2.","summary":"HMPL-306 is a small-molecule drug developed by Hutchmed. Its target is IDH1 / IDH2 (the sponsor names IDH1/IDH2 (mutant)). ClinicalTrials.gov describes the intervention as: Patients will receive HMPL-306 monotherapy: HMPL-306 PO at 250 mg QD (C1) + 150 mg QD (starting from C2), 28 days as a cycle. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06387069 (A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukaemia), in acute myeloid leukaemia. The largest, NCT06387069, plans to enrol 316 participants with primary completion expected 2028-12-31. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of HMPL-306","url":"https://clinicaltrials.gov/search?intr=HMPL-306"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":["idh"],"drugs":[],"companies":["hutchmed"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06387069"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"small molecule","mechanism":"Small-molecule drug directed at IDH1 / IDH2, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/hmpl-306/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"target":[{"id":"idh","kind":"target","name":"IDH1 / IDH2","route":"/targets/idh/"}],"company":[{"id":"hutchmed","kind":"company","name":"Hutchmed","route":"/companies/hutchmed/"}],"trial":[{"id":"nct06387069","kind":"trial","name":"A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia","route":"/trials/nct06387069/"}]}}